vs
MKS INC（MKSI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
MKS INC的季度营收约是Revvity的1.3倍（$1.0B vs $772.1M），Revvity净利率更高（12.7% vs 10.3%，领先2.4%），MKS INC同比增速更快（10.6% vs 5.9%），Revvity自由现金流更多（$161.8M vs $92.0M），过去两年MKS INC的营收复合增速更高（9.1% vs 9.0%）
MKS Inc原是跨国独立软件供应商，业务覆盖应用生命周期管理（ALM）及系统管理两大领域，2011年5月31日被参数技术公司（PTC, Inc.）收购，目前为PTC旗下子公司。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MKSI vs RVTY — 直观对比
营收规模更大
MKSI
是对方的1.3倍
$772.1M
营收增速更快
MKSI
高出4.7%
5.9%
净利率更高
RVTY
高出2.4%
10.3%
自由现金流更多
RVTY
多$69.8M
$92.0M
两年增速更快
MKSI
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $772.1M |
| 净利润 | $107.0M | $98.4M |
| 毛利率 | 46.3% | — |
| 营业利润率 | 13.9% | 14.5% |
| 净利率 | 10.3% | 12.7% |
| 营收同比 | 10.6% | 5.9% |
| 净利润同比 | 18.9% | 3.9% |
| 每股收益（稀释后） | $1.58 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MKSIRVTY
| Q4 25 | $1.0B | $772.1M | ||
| Q3 25 | $988.0M | $698.9M | ||
| Q2 25 | $973.0M | $720.3M | ||
| Q1 25 | $936.0M | $664.8M | ||
| Q4 24 | $935.0M | $729.4M | ||
| Q3 24 | $896.0M | $684.0M | ||
| Q2 24 | $887.0M | $691.7M | ||
| Q1 24 | $868.0M | $649.9M |
净利润MKSIRVTY
| Q4 25 | $107.0M | $98.4M | ||
| Q3 25 | $74.0M | $46.7M | ||
| Q2 25 | $62.0M | $53.9M | ||
| Q1 25 | $52.0M | $42.2M | ||
| Q4 24 | $90.0M | $94.6M | ||
| Q3 24 | $62.0M | $94.4M | ||
| Q2 24 | $23.0M | $55.4M | ||
| Q1 24 | $15.0M | $26.0M |
毛利率MKSIRVTY
| Q4 25 | 46.3% | — | ||
| Q3 25 | 46.7% | 53.6% | ||
| Q2 25 | 46.6% | 54.5% | ||
| Q1 25 | 47.4% | 56.5% | ||
| Q4 24 | 47.3% | — | ||
| Q3 24 | 48.2% | 56.3% | ||
| Q2 24 | 47.2% | 55.7% | ||
| Q1 24 | 47.8% | 54.6% |
营业利润率MKSIRVTY
| Q4 25 | 13.9% | 14.5% | ||
| Q3 25 | 14.0% | 11.7% | ||
| Q2 25 | 13.9% | 12.6% | ||
| Q1 25 | 11.9% | 10.9% | ||
| Q4 24 | 14.7% | 16.3% | ||
| Q3 24 | 14.3% | 14.3% | ||
| Q2 24 | 14.3% | 12.4% | ||
| Q1 24 | 12.2% | 6.8% |
净利率MKSIRVTY
| Q4 25 | 10.3% | 12.7% | ||
| Q3 25 | 7.5% | 6.7% | ||
| Q2 25 | 6.4% | 7.5% | ||
| Q1 25 | 5.6% | 6.4% | ||
| Q4 24 | 9.6% | 13.0% | ||
| Q3 24 | 6.9% | 13.8% | ||
| Q2 24 | 2.6% | 8.0% | ||
| Q1 24 | 1.7% | 4.0% |
每股收益（稀释后）MKSIRVTY
| Q4 25 | $1.58 | $0.86 | ||
| Q3 25 | $1.10 | $0.40 | ||
| Q2 25 | $0.92 | $0.46 | ||
| Q1 25 | $0.77 | $0.35 | ||
| Q4 24 | $1.34 | $0.77 | ||
| Q3 24 | $0.92 | $0.77 | ||
| Q2 24 | $0.33 | $0.45 | ||
| Q1 24 | $0.22 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $418.0M | $919.9M |
| 总债务越低越好 | $4.2B | — |
| 股东权益账面价值 | $2.7B | $7.3B |
| 总资产 | $8.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.53× | — |
8季度趋势，按日历期对齐
现金及短期投资MKSIRVTY
| Q4 25 | $418.0M | $919.9M | ||
| Q3 25 | $413.0M | $931.4M | ||
| Q2 25 | $498.0M | $991.8M | ||
| Q1 25 | $407.0M | $1.1B | ||
| Q4 24 | $420.0M | $1.2B | ||
| Q3 24 | $439.0M | $1.2B | ||
| Q2 24 | $506.0M | $2.0B | ||
| Q1 24 | $1.0M | $1.7B |
总债务MKSIRVTY
| Q4 25 | $4.2B | — | ||
| Q3 25 | $4.3B | — | ||
| Q2 25 | $4.4B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.8B | — | ||
| Q2 24 | $4.8B | — | ||
| Q1 24 | $4.7B | — |
股东权益MKSIRVTY
| Q4 25 | $2.7B | $7.3B | ||
| Q3 25 | $2.6B | $7.4B | ||
| Q2 25 | $2.6B | $7.6B | ||
| Q1 25 | $2.4B | $7.6B | ||
| Q4 24 | $2.3B | $7.7B | ||
| Q3 24 | $2.4B | $7.9B | ||
| Q2 24 | $2.2B | $7.9B | ||
| Q1 24 | $2.4B | $7.8B |
总资产MKSIRVTY
| Q4 25 | $8.8B | $12.2B | ||
| Q3 25 | $8.8B | $12.1B | ||
| Q2 25 | $8.8B | $12.4B | ||
| Q1 25 | $8.6B | $12.4B | ||
| Q4 24 | $8.6B | $12.4B | ||
| Q3 24 | $9.0B | $12.8B | ||
| Q2 24 | $8.9B | $13.4B | ||
| Q1 24 | $8.9B | $13.4B |
负债/权益比MKSIRVTY
| Q4 25 | 1.53× | — | ||
| Q3 25 | 1.64× | — | ||
| Q2 25 | 1.71× | — | ||
| Q1 25 | 1.87× | — | ||
| Q4 24 | 1.93× | — | ||
| Q3 24 | 1.98× | — | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | 1.94× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $142.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $92.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 8.9% | 21.0% |
| 资本支出强度资本支出/营收 | 4.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.33× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $497.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流MKSIRVTY
| Q4 25 | $142.0M | $182.0M | ||
| Q3 25 | $197.0M | $138.5M | ||
| Q2 25 | $165.0M | $134.3M | ||
| Q1 25 | $141.0M | $128.2M | ||
| Q4 24 | $176.0M | $174.2M | ||
| Q3 24 | $163.0M | $147.9M | ||
| Q2 24 | $122.0M | $158.6M | ||
| Q1 24 | $67.0M | $147.6M |
自由现金流MKSIRVTY
| Q4 25 | $92.0M | $161.8M | ||
| Q3 25 | $146.0M | $120.0M | ||
| Q2 25 | $136.0M | $115.5M | ||
| Q1 25 | $123.0M | $112.2M | ||
| Q4 24 | $125.0M | $149.8M | ||
| Q3 24 | $141.0M | $125.6M | ||
| Q2 24 | $95.0M | $136.6M | ||
| Q1 24 | $49.0M | $129.7M |
自由现金流率MKSIRVTY
| Q4 25 | 8.9% | 21.0% | ||
| Q3 25 | 14.8% | 17.2% | ||
| Q2 25 | 14.0% | 16.0% | ||
| Q1 25 | 13.1% | 16.9% | ||
| Q4 24 | 13.4% | 20.5% | ||
| Q3 24 | 15.7% | 18.4% | ||
| Q2 24 | 10.7% | 19.7% | ||
| Q1 24 | 5.6% | 20.0% |
资本支出强度MKSIRVTY
| Q4 25 | 4.8% | 2.6% | ||
| Q3 25 | 5.2% | 2.6% | ||
| Q2 25 | 3.0% | 2.6% | ||
| Q1 25 | 1.9% | 2.4% | ||
| Q4 24 | 5.5% | 3.4% | ||
| Q3 24 | 2.5% | 3.3% | ||
| Q2 24 | 3.0% | 3.2% | ||
| Q1 24 | 2.1% | 2.7% |
现金转化率MKSIRVTY
| Q4 25 | 1.33× | 1.85× | ||
| Q3 25 | 2.66× | 2.97× | ||
| Q2 25 | 2.66× | 2.49× | ||
| Q1 25 | 2.71× | 3.03× | ||
| Q4 24 | 1.96× | 1.84× | ||
| Q3 24 | 2.63× | 1.57× | ||
| Q2 24 | 5.30× | 2.87× | ||
| Q1 24 | 4.47× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MKSI
| Electronics And Packaging | $303.0M | 29% |
| Specialty Industrial | $295.0M | 29% |
| Photonics Solutions Division | $274.0M | 26% |
| Services | $125.0M | 12% |
| Other | $37.0M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
